The cardiometabolic-based chronic disease model lays the foundations for accurate, evidence-based preventive targeting and gene therapy.

The cardiometabolic-based chronic disease model lays the foundations for accurate, evidence-based preventive targeting in order to develop a gene therapeutic plan that promotes cardiometabolic health thereby lowering the risk of CVD onset and complications. This approach is useful for clinical trial design, knowledge translation, and patient education because of its methodological formalism, which can be refined over time. A step-by-step structure for cardiometabolic-based chronic disease is explored in the first part of this Review, concentrating on two main drivers, adiposity and dysglycemia, as they contribute to three major CVD problems: CHD, HF, and AF. The relevant molecular, biochemical, and physiological pathways are discussed before being broken down into clinical targets. The aim of the cardiometabolic-based chronic disease model is to produce long-term, optimum CV outcomes as well as benefit from gene therapy by avoiding disease as soon as possible.

Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents

Key Points MMB ameliorates anemia in a rodent anemia of chronic disease model by inhibiting activin receptor-like kinase-2 activity. Hepcidin-dependent ferroportin degradation is independent of JAK2 phosphorylation.